Wall Street analyst estimates for Teleflex Incorporated (TFX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $1.90 | ||
| 2026-08-06 | $1.76 | $1.28 | +37.5% |
| 2026-05-07 | $1.39 | $1.21 | +14.9% |
| 2026-02-26 | $1.93 | $3.73 | -48.3% |
| 2025-11-06 | $3.67 | $3.38 | +8.6% |
| 2025-07-31 | $3.73 | $3.36 | +11.0% |
| 2025-05-01 | $2.91 | $2.88 | +1.0% |
| 2025-02-27 | $3.89 | $3.86 | +0.8% |
Valuation Ratios
| Price / Book | 1.86 |
| EV / EBITDA | -33.89 |
| Dividend Yield | 1.10% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.87B | $2.15B | $2.45B | $2.60B | $2.54B | $2.81B | $2.79B | $2.97B | $3.05B | $1.99B |
| Cost of Revenue | $871.8M | $974.5M | $1.06B | $1.19B | $1.21B | $1.26B | $1.26B | $1.33B | $1.34B | $872.0M |
| Gross Profit | $996.2M | $1.17B | $1.38B | $1.41B | $1.32B | $1.55B | $1.53B | $1.65B | $1.70B | $1.12B |
| Research & Development | $58.6M | $84.8M | $106.2M | $113.9M | $119.7M | $130.8M | $153.8M | $154.4M | $161.7M | $144.8M |
| Selling, General & Admin | $563.3M | $700.0M | $878.7M | $851.8M | $743.6M | $860.1M | $863.7M | $929.9M | $995.3M | $720.2M |
| Operating Expenses | $621.9M | $784.7M | $984.9M | $981.8M | $901.8M | $921.5M | $1.03B | $1.14B | $1.55B | $865.0M |
| Operating Income | $319.5M | $372.3M | $321.7M | $427.3M | $423.1M | $628.1M | $499.7M | $506.3M | $151.0M | $255.8M |
| EBITDA | $418.6M | $522.7M | $532.6M | $634.2M | $651.5M | $853.8M | $730.8M | $761.2M | $433.6M | $302.5M |
| Interest Expense | $54.9M | $82.5M | $103.0M | $80.3M | $66.5M | $57.0M | $54.3M | $85.1M | $83.5M | $100.2M |
| Pre-tax Income | $245.7M | $284.9M | $219.6M | $339.9M | $357.7M | $559.5M | $445.9M | $434.0M | $75.5M | $24.6M |
| Income Tax | $8.1M | $129.6M | $23.2M | -$122.1M | $21.9M | $74.3M | $83.0M | $76.4M | $5.3M | -$34.0M |
| Net Income | $237.4M | $152.5M | $200.8M | $461.5M | $335.3M | $485.4M | $363.1M | $356.3M | $69.7M | -$905.6M |
| EPS | $5.48 | $3.39 | $4.39 | $9.99 | $7.21 | $10.38 | $7.74 | $7.58 | $1.49 | $-20.30 |
| EPS (Diluted) | $4.98 | $3.27 | $4.29 | $9.80 | $7.09 | $10.23 | $7.68 | $7.53 | $1.48 | $-20.25 |
| Shares Outstanding (Diluted) | $47.6M | $46.7M | $46.8M | $47.1M | $47.3M | $47.4M | $47.3M | $47.3M | $47.1M | $44.7M |
Price
| Price | $125.24 |
| Market Cap | $5.5B |
| Exchange | NYSE |
| Country | US |
Related companies: ALKS · ARWR · BLCO · CRSP · KRYS · MMSI · PCVX
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of TFX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks